1. In Vivo
  2. >>Archive

BNP: Can Competitors Catch Up to Biosite?

Biosite has spent the last year building demand for its point-of-care testing (POCT) cardiac marker for chronic heart failure, BNP. The test is poised to be a major successs for Biosite, not least because it has semi-exclusive licensing rights (from Scios), which limit competition and because of the perceived value of its clinical utility. It could be a major victory for a small POCT company. But for Biosite, the hard part is just beginning as competition surfaces from other licensees and similar markers. Most immediately, Roche just launched a similar marker and is gearing up for battle.

Plucky Biosite Inc. has been more successful than most diagnostics companies at grabbing the jackpot—ownership of proprietary, novel, high-value biomarkers with widespread clinical utility. (See "Biosite's Play for High-Value Diagnostics," IN VIVO, April 1999 Also see "BioSite's Play for High-Value Diagnostics" - In Vivo, 1 April, 1999..) Such markers rarely come along. But for nearly two years, the point-of-care testing (POCT) company has been the only provider of B-type natriuretic peptide (BNP), a blood test that is used to diagnose patients with congestive heart failure (CHF) and stratify the severity of their disease.

With excitement about it building for more than a year, BNP seems poised to enter the rarified world of tests...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.